Hypertrophic and Keloid Scar Treatment

Hypertrophic and Keloid Scar Treatment Market Outlook

The global hypertrophic and keloid scar treatment market is poised for significant expansion, projected to reach USD 6.5 billion by 2035, growing at a CAGR of 8.2% during the forecast period of 2025 to 2035. This growth is primarily driven by increasing awareness about minimally invasive procedures and advancements in medical technology. Moreover, a rise in the incidence of skin injuries and surgeries resulting in scarring, coupled with the growing demand for aesthetically pleasing outcomes, has further fueled market growth. The increasing adoption of innovative treatment methodologies and an uptick in healthcare expenditure across various regions are also contributing to the market expansion. Additionally, the market is witnessing a surge in demand for personalized treatment options, which has encouraged key players to innovate and enhance their product offerings in this domain.

Growth Factor of the Market

A significant growth factor for the hypertrophic and keloid scar treatment market is the rising prevalence of conditions leading to scarring, such as traumatic injuries, surgical procedures, and burns. As more individuals seek effective treatment alternatives, healthcare professionals are responding with advanced solutions tailored to patient needs. Moreover, the increasing focus on aesthetic outcomes has led to the development of sophisticated products designed not just for efficacy but also for improved patient experience. Additionally, the integration of technology into treatment modalities, such as laser therapy and injectable treatments, is driving higher patient engagement and acceptance. The growing trend towards preventative skincare and the influence of social media in raising awareness about scar treatments further contribute to the market's positive outlook. Furthermore, the expansion of distribution channels and the growing number of specialty clinics are making these treatments more accessible to a broader population.

Key Highlights of the Market

• Projected market value of USD 6.5 billion by 2035, with a CAGR of 8.2% from 2025 to 2035.
• Increased adoption of innovative and minimally invasive treatment options.
• Rising consumer awareness about scar treatment solutions and aesthetic improvements.
• Advancements in medical technology enhancing treatment efficacy and patient compliance.
• Expanding healthcare infrastructure providing improved access to treatments globally.

By Product Type

Creams & Ointments:

Creams and ointments represent a significant segment in the hypertrophic and keloid scar treatment market, primarily due to their ease of application and effectiveness. These topical treatments often contain active ingredients such as silicone, corticosteroids, and various botanical extracts, which help in softening the scar tissue and reducing inflammation. The growing trend towards at-home care solutions has made these products increasingly popular among consumers looking for non-invasive treatment options. Furthermore, innovations in formulations, including advanced delivery systems that enhance penetration and efficacy, have propelled the demand for these products. The affordability and wide availability of creams and ointments across various retail channels add to their appeal, making them a preferred choice for many patients. Additionally, continuous marketing efforts and endorsements by dermatologists have further solidified their presence in the market.

Gel Sheets:

Gel sheets are another indispensable product type within the hypertrophic and keloid scar treatment market, known for their ability to provide an optimal healing environment. Made primarily from silicone, these sheets adhere to the scar and create a protective barrier that helps to hydrate the scar tissue, thereby improving its appearance over time. They are particularly favored for their convenience and ability to be worn discreetly under clothing. As patients increasingly opt for solutions that fit seamlessly into their lifestyle, the demand for gel sheets is on the rise. Moreover, product innovations, such as self-adhesive backing and customizable sizes, have made gel sheets more user-friendly and effective. The rising awareness about the importance of scar management post-surgery has also contributed to the growth of this segment, as healthcare providers recommend them for both surgical and non-surgical scars.

Silicone Gel:

Silicone gel is widely recognized for its efficacy in treating hypertrophic and keloid scars, making it a prominent product type in the market. This gel form allows for easy application and quick absorption, providing a soothing effect on the skin. Silicone gel works by forming a protective layer over the scar, which not only helps in flattening the scar but also reduces redness and discomfort. The increasing endorsement from healthcare professionals and the positive clinical evidence supporting silicone gel's effectiveness have significantly boosted its popularity among consumers. Furthermore, the emergence of combination therapies, where silicone gel is used alongside other treatments, is enhancing its functionality and appeal. As consumers become more informed about scar treatment options, the preference for silicone gel is expected to grow, driven by its proven track record.

Pressure Garments:

Pressure garments are a specialized product type used primarily in the treatment of severe scars, particularly for patients with post-surgical or burn scars. These garments apply consistent pressure to the scarred area, which helps to flatten and soften the scar over time. The utilization of pressure garments is especially prevalent in clinical settings, where healthcare professionals prescribe them as part of a comprehensive scar management program. The increasing prevalence of burn incidents and reconstructive surgeries has created a wider market for these garments. Additionally, advancements in fabric technology have led to the development of more comfortable and breathable pressure garments, which improves patient compliance. As awareness about the effectiveness of pressure therapy grows, this segment is likely to witness further expansion in the coming years.

Laser Therapy:

Laser therapy is a cutting-edge and highly effective method for treating hypertrophic and keloid scars, gaining significant traction in the market. This procedure utilizes focused light energy to target scar tissue, promoting collagen remodeling and reducing the appearance of scars. The appeal of laser therapy lies in its minimally invasive nature and the rapid results it can achieve, making it a preferred option for many patients seeking cosmetic improvements. With advances in laser technology, including fractional lasers and pulsed dye lasers, the efficacy and safety profiles have improved significantly. Increasingly, dermatologists and plastic surgeons are adopting laser therapy as part of their treatment regimens, further driving the market growth. As more individuals become aware of their options, the demand for laser therapies is expected to rise, supported by ongoing clinical studies demonstrating their effectiveness.

By Application

Hypertrophic Scars:

The treatment of hypertrophic scars forms a crucial segment of the scar treatment market, focusing on scars that elevate above the skin surface and often become red or darker than the surrounding skin. Various treatment modalities are employed to address these types of scars, including topical treatments, silicone gel sheets, and laser therapy. The rising awareness of the psychological impact that hypertrophic scars can have on individuals drives demand for effective treatment options. Healthcare providers are increasingly recommending early intervention strategies to minimize the development of hypertrophic scars, contributing to the growth of this segment. Furthermore, the incorporation of patient education programs about hypertrophic scars and available treatment options is fostering proactive management and treatment-seeking behavior among patients.

Keloid Scars:

Keloid scars, characterized by their thick, raised appearance and tendency to spread beyond the original injury site, require specialized treatment approaches distinct from hypertrophic scars. This application segment is particularly significant due to the challenges that keloid scars present, including their recurrent nature and resistance to treatment. Common treatment modalities for keloid scars include corticosteroid injections, silicone gel sheets, and surgical excision, often combined with post-operative therapies like radiation. The increasing prevalence of conditions leading to keloid formation, such as acne and surgical interventions, has resulted in heightened demand for effective treatment solutions. Additionally, ongoing research focused on understanding the underlying mechanisms of keloid formation is likely to lead to the development of more targeted therapies, further enhancing this segment's growth prospects.

By Treatment Type

Topical Treatment:

Topical treatments are among the most commonly utilized methods for scar management, offering non-invasive options that can be administered at home. These treatments often include creams, ointments, and silicone products that work on the surface of the skin, helping to hydrate and flatten scars over time. The ease of application and low-cost nature of topical treatments make them attractive to a wide demographic, particularly among those seeking to manage minor scars. Furthermore, the growing inclination towards preventive care is encouraging individuals to start using topical treatments post-injury or surgery to minimize scar formation. As healthcare professionals continue to advocate for early intervention strategies, the demand for topical treatments is anticipated to increase, reinforcing their position in the market.

Surgical Treatment:

Surgical treatment plays a vital role in managing significant hypertrophic and keloid scars, particularly when non-invasive methods fail to deliver satisfactory results. This treatment type typically involves excision of the scar tissue, often followed by various adjunctive therapies to prevent recurrence. Surgical intervention is considered when scars cause physical discomfort or emotional distress, driving patients to seek more permanent solutions. The increasing focus on cosmetic outcomes in reconstructive surgery has led to an uptick in demand for surgical scar revision procedures. Additionally, advances in surgical techniques and postoperative care have improved outcomes, encouraging more patients to consider surgical options for their scar management. The growing prevalence of surgical procedures across various medical fields further supports the expansion of this treatment segment.

Laser Treatment:

Laser treatment remains one of the most advanced and sought-after methods for scar management, leveraging focused light technology to promote skin remodeling and reduce scar visibility. This treatment type is particularly effective for both hypertrophic and keloid scars, with different laser modalities tailored to individual patient needs. The popularity of laser treatment has surged as patients seek quick results and a minimally invasive approach. The continuous developments in laser technology have enhanced safety profiles and treatment effectiveness, making it a favorable option among practitioners. As dermatologists and plastic surgeons adopt laser therapy into their practice, patient outcomes have improved, leading to positive word-of-mouth and increased demand. Furthermore, ongoing research and clinical trials are likely to introduce new laser options, expanding the treatment landscape for scar management.

Injectable Treatment:

Injectable treatments, including corticosteroids and other fillers, are increasingly recognized as effective options for managing hypertrophic and keloid scars. These treatments target the underlying scar tissue, helping to flatten and soften the raised areas. Corticosteroid injections are particularly popular for keloid management, reducing inflammation and scar tissue formation. The appeal of injectable treatments lies in their ability to provide rapid results with minimal downtime, making them suitable for patients with busy lifestyles. The rising trend towards combination therapies, where injectables are used alongside surgical or laser treatments, is enhancing their effectiveness and encouraging more patients to explore these options. As aesthetic considerations become more prominent in medical settings, the demand for injectable treatments for scar management is expected to grow.

Cryotherapy:

Cryotherapy has emerged as a valuable treatment option for hypertrophic and keloid scars, utilizing extreme cold to reduce scar tissue and promote skin healing. This method is particularly effective for treating keloids, as the cold temperature can inhibit collagen production and help to flatten the raised area. Cryotherapy is often used in conjunction with other treatments, such as corticosteroid injections, to enhance overall effectiveness. The non-invasive nature of cryotherapy appeals to patients looking for alternatives to more invasive procedures. As awareness about the benefits of cryotherapy increases and more clinics adopt this technique, its presence in the scar treatment market is likely to expand. The continuous evolution of cryotherapy technology and techniques will likely further boost its application in scar management.

By User

Hospitals:

Hospitals represent a critical user segment in the hypertrophic and keloid scar treatment market, providing comprehensive care for patients requiring specialized interventions. In hospital settings, patients receive a variety of treatment modalities, including surgical excisions, laser therapies, and injectable treatments conducted by experienced healthcare professionals. The integrated approach provides patients with tailored treatment plans that cater to their specific scar types and severity. The increasing prevalence of surgical procedures and trauma cases treated in hospitals is driving demand for advanced scar management solutions within these facilities. Furthermore, hospitals often serve as primary care centers where patients receive referrals to specialized dermatology or plastic surgery departments, enhancing the overall treatment landscape.

Clinics:

Specialty clinics are rapidly gaining recognition as a vital user segment in the hypertrophic and keloid scar treatment market, focusing specifically on aesthetic and dermatological treatments. These clinics often provide a diverse range of treatment options, including laser therapies, injectable treatments, and topical solutions, catering to patients seeking cosmetic improvements. The growing consumer demand for non-invasive procedures has led to the proliferation of clinics offering scar management services, creating a competitive landscape. Furthermore, the personalized care provided in clinic settings often results in higher patient satisfaction rates, driving repeat visits and referrals. With advancements in technology and treatment techniques, clinics are poised to capture a growing share of the market as patients actively seek specialized scar treatment solutions.

Dermatology Centers:

Dermatology centers represent a significant user segment dedicated to managing various skin conditions, including hypertrophic and keloid scars. These centers house trained professionals who specialize in skin health and are proficient in deploying innovative treatment methods tailored to individual patient needs. The increasing focus on dermatological aesthetics and the importance of skin health are enhancing the demand for specialized scar treatments within these facilities. Dermatology centers often offer a comprehensive suite of care options, including topical treatments, laser therapies, and injectable options, catering to diverse patient preferences. Additionally, as awareness about the importance of expert care in scar management grows, more patients are turning to dermatology centers for effective treatment solutions, driving further market growth.

By Region

The regional analysis of the hypertrophic and keloid scar treatment market reveals distinct growth patterns and preferences influenced by local healthcare infrastructure and consumer awareness. North America holds the largest market share, primarily driven by the presence of advanced healthcare facilities and a high prevalence of dermatological conditions leading to scarring. The market in this region is expected to grow at a CAGR of 7.8% during the forecast period. Increased expenditure on healthcare and a growing emphasis on aesthetic solutions are contributing to this rapid growth. Europe follows closely, characterized by a well-established healthcare system and a rising number of patients seeking cosmetic enhancements, further propelling the demand for effective scar treatments.

In the Asia Pacific region, the market is witnessing the fastest growth rate, driven by an expanding middle class and increasing awareness about scar treatment options. The proliferation of skincare clinics and dermatology centers in countries like China and India is enhancing access to advanced treatment modalities. Additionally, Latin America and the Middle East & Africa are also emerging markets for hypertrophic and keloid scar treatments, supported by an increasing focus on cosmetic procedures and improved healthcare access. However, the overall market size in these regions is comparatively smaller than their North American and European counterparts. The growth trajectory in these regions is expected to gain momentum as consumer awareness and healthcare infrastructure continue to develop.

Opportunities

The hypertrophic and keloid scar treatment market presents numerous opportunities, particularly through the adoption of innovative technologies that enhance treatment efficacy. The development of new formulations and delivery systems, such as microneedling with topical agents or advanced laser technologies, is creating avenues for more effective scar management options. Moreover, the rising trend of personalized medicine is allowing for tailored treatment plans that cater to individual patient characteristics, improving overall outcomes and satisfaction. As healthcare professionals increasingly recognize the importance of early intervention in scar management, new educational programs aimed at both patients and providers can open up additional avenues for growth. Furthermore, the increasing prevalence of conditions that result in scarring, such as obesity-related surgeries and skin traumas, is likely to further propel the market as healthcare systems adapt to meet this growing demand.

Another promising opportunity lies in the expansion of distribution channels, including e-commerce platforms that allow consumers easier access to scar treatment products. The rise of telemedicine also presents a unique opening for healthcare providers to offer consultations and management plans remotely, especially for patients in underserved areas. As convenience and accessibility become focal points in patient care, leveraging these trends will be essential for companies looking to thrive in the market. Additionally, the growing interest in holistic and alternative treatment options could encourage the integration of complementary therapies alongside traditional scar treatments, expanding the overall market landscape and attracting a wider patient base.

Threats

Despite the opportunities, the hypertrophic and keloid scar treatment market faces several threats that could hinder its growth. One major challenge is the increasing competition among key players, leading to price wars that could potentially compromise product quality and innovation. With numerous brands vying for market share, maintaining product efficacy while managing operational costs is becoming increasingly difficult. Moreover, regulatory hurdles and stringent approval processes for new treatments can slow down the introduction of innovative products, limiting the ability of companies to respond to evolving consumer needs promptly. Additionally, varying levels of healthcare access and affordability across different regions can create disparities in treatment adoption, potentially leaving certain patient populations underserved.

Another significant threat stems from the potential for adverse effects associated with some scar treatments, particularly surgical and invasive procedures. Reports of complications or unsatisfactory results can lead to decreased consumer confidence in certain treatment modalities, affecting overall market demand. As patients become more informed through various channels, including online platforms, they may become more selective in choosing treatment options based on perceived safety and efficacy. Furthermore, the economic impact of global events, such as pandemics or economic downturns, can significantly affect healthcare spending, leading to reduced investment in non-essential procedures, including aesthetic treatments for scars. Companies must remain vigilant and adaptable to these threats to sustain growth in this dynamic market.

Competitor Outlook

• Allergan
• Merz Pharmaceuticals
• Revance Therapeutics
• Dermatology Partners
• Silagen
• ScarHeal
• Stratpharma
• Hyaluronic Acid Co.
• Integra LifeSciences
• Hologic
• Galderma
• Valeant Pharmaceuticals
• Smith & Nephew
• 3M Healthcare
• BSN Medical

The competitive landscape of the hypertrophic and keloid scar treatment market is characterized by a diverse range of companies, each striving to capture market share through innovative solutions and effective marketing strategies. Major players are focusing on research and development initiatives to create advanced products that address specific consumer needs. Partnerships and collaborations among companies, healthcare professionals, and academic institutions are becoming increasingly common, aimed at enhancing product development and expanding market reach. Moreover, branding and consumer engagement through social media and online platforms have become vital in attracting and retaining customers, allowing companies to build strong brand loyalty in a highly competitive environment.

Among the leading companies, Allergan stands out with its extensive portfolio of aesthetic treatments, including injectable solutions such as Botox and dermal fillers that are often utilized in scar management. The company invests heavily in marketing and educational initiatives, helping to shape consumer perceptions and driving demand for its products. Merz Pharmaceuticals follows closely, recognized for its innovative product lines, including silicone-based scar management solutions that are well-regarded within the dermatology community. Revance Therapeutics is making a mark with its cutting-edge technologies in the injectable space, striving to provide advanced options for dermatologists and patients alike. Each of these companies is positioned to leverage their strengths in innovation and marketing to pave the way for growth in the scar treatment market.

Furthermore, companies like Galderma and Smith & Nephew are leveraging their expertise in wound care and dermatology to enhance their product offerings and expand their market presence. Galderma, known for its dermatological solutions, is increasingly focusing on scar treatment products that cater to both medical and aesthetic needs. Smith & Nephew's extensive experience in wound management and surgical products places it in a solid position to address the growing demand for effective scar interventions. As the market evolves, these companies, alongside newer entrants, will likely continue to push the boundaries of innovation and improve treatment outcomes for individuals with hypertrophic and keloid scars.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Hologic
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Silagen
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Allergan
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Galderma
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 ScarHeal
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 BSN Medical
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Stratpharma
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 3M Healthcare
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Smith & Nephew
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Hyaluronic Acid Co.
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Dermatology Partners
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Integra LifeSciences
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Merz Pharmaceuticals
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Revance Therapeutics
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Valeant Pharmaceuticals
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Hypertrophic and Keloid Scar Treatment Market, By User
    • 6.1.1 Hospitals
    • 6.1.2 Clinics
    • 6.1.3 Dermatology Centers
  • 6.2 Hypertrophic and Keloid Scar Treatment Market, By Application
    • 6.2.1 Hypertrophic Scars
    • 6.2.2 Keloid Scars
  • 6.3 Hypertrophic and Keloid Scar Treatment Market, By Product Type
    • 6.3.1 Creams & Ointments
    • 6.3.2 Gel Sheets
    • 6.3.3 Silicone Gel
    • 6.3.4 Pressure Garments
    • 6.3.5 Laser Therapy
  • 6.4 Hypertrophic and Keloid Scar Treatment Market, By Treatment Type
    • 6.4.1 Topical Treatment
    • 6.4.2 Surgical Treatment
    • 6.4.3 Laser Treatment
    • 6.4.4 Injectable Treatment
    • 6.4.5 Cryotherapy

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Hypertrophic and Keloid Scar Treatment Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Hypertrophic and Keloid Scar Treatment market is categorized based on

By Product Type

• Creams & Ointments
• Gel Sheets
• Silicone Gel
• Pressure Garments
• Laser Therapy

By Application

• Hypertrophic Scars
• Keloid Scars

By Treatment Type

• Topical Treatment
• Surgical Treatment
• Laser Treatment
• Injectable Treatment
• Cryotherapy

By User

• Hospitals
• Clinics
• Dermatology Centers

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Allergan
• Merz Pharmaceuticals
• Revance Therapeutics
• Dermatology Partners
• Silagen
• ScarHeal
• Stratpharma
• Hyaluronic Acid Co.
• Integra LifeSciences
• Hologic
• Galderma
• Valeant Pharmaceuticals
• Smith & Nephew
• 3M Healthcare
• BSN Medical